Limits...
Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases.

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K - Pulm Med (2012)

Bottom Line: The most commonly observed late effect was radiation pneumonitis.No other ≧ grade 3 acute and late adverse events occurred.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT
Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1-90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75-99%) and 65% (95% CI, 48-82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) <31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI ≧31.9 months (P < 0.05). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.

No MeSH data available.


Related in: MedlinePlus

Overall survival and local control of 42 patients with oligo-recurrence cancer in the lung.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3472526&req=5

fig1: Overall survival and local control of 42 patients with oligo-recurrence cancer in the lung.

Mentions: No other grade ≥3 acute side effects occurred. Twenty-one patients (50%) and 5 patients (12%) experienced grade 1 and 2 adverse event after irradiation of metastases, respectively. Of the 42 patients, 21 patients (50%) and 3 patients (7%) displayed grade 1 pneumonitis (asymptomatic, radiographic findings only) and grade 2 pneumonitis (symptomatic, not interfering with activities of daily living), respectively. No grade ≥3 late adverse events occurred until now. The medianduration of follow-up was 20 months (range, 1–90 months) for all patients and 24 months (range, 6–90 months) for those alive. The 1- and 2-year local control rates were 91% (95% CI, 82–100%) and 87% (95% CI, 75–99%), respectively (Figure 1). At the time of last follow-up, 16 patients had died. The causes of death were recurrence (n = 9), other diseases (n = 7). The overall 1- and 2-year survival rates were 81% (95% CI, 69–94%) and 65% (95% CI, 48–82%), respectively (Figure 1), with a median survival time of 40 months. Seventeen of 42 patients showed a long-term survival of longer than 2 years.


Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases.

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K - Pulm Med (2012)

Overall survival and local control of 42 patients with oligo-recurrence cancer in the lung.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3472526&req=5

fig1: Overall survival and local control of 42 patients with oligo-recurrence cancer in the lung.
Mentions: No other grade ≥3 acute side effects occurred. Twenty-one patients (50%) and 5 patients (12%) experienced grade 1 and 2 adverse event after irradiation of metastases, respectively. Of the 42 patients, 21 patients (50%) and 3 patients (7%) displayed grade 1 pneumonitis (asymptomatic, radiographic findings only) and grade 2 pneumonitis (symptomatic, not interfering with activities of daily living), respectively. No grade ≥3 late adverse events occurred until now. The medianduration of follow-up was 20 months (range, 1–90 months) for all patients and 24 months (range, 6–90 months) for those alive. The 1- and 2-year local control rates were 91% (95% CI, 82–100%) and 87% (95% CI, 75–99%), respectively (Figure 1). At the time of last follow-up, 16 patients had died. The causes of death were recurrence (n = 9), other diseases (n = 7). The overall 1- and 2-year survival rates were 81% (95% CI, 69–94%) and 65% (95% CI, 48–82%), respectively (Figure 1), with a median survival time of 40 months. Seventeen of 42 patients showed a long-term survival of longer than 2 years.

Bottom Line: The most commonly observed late effect was radiation pneumonitis.No other ≧ grade 3 acute and late adverse events occurred.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT
Purpose. To investigate the outcome and toxicity of stereotactic body radiotherapy (SBRT) in patients with oligo-recurrence cancer in the lung (ORCL). Methods and Materials. A retrospective review of 42 patients with ORCL who underwent SBRT in our two hospitals was conducted. We evaluated the outcome and adverse effects after SBRT for ORCL. Results. All patients finished their SBRT course without interruptions of toxicity reasons. The median follow-up period was 20 months (range, 1-90 months). The 2-year local control rate and overall survival were 87% (95% CI, 75-99%) and 65% (95% CI, 48-82%). As for prognostic factor, the OS of patients with a short disease-free interval (DFI) <31.9 months, between the initial therapy and SBRT for ORCL, was significantly worse than the OS of long DFI ≧31.9 months (P < 0.05). The most commonly observed late effect was radiation pneumonitis. One patient had grade 4 gastrointestinal toxicity (perforation of gastric tube). No other ≧ grade 3 acute and late adverse events occurred. There were no treatment-related deaths during this study. Conclusions. In patients with ORCL, radical treatment with SBRT is safe and provides a chance for long-term survival by offering favorable local control.

No MeSH data available.


Related in: MedlinePlus